Rapid Sequencing of Approved Therapies in Patients with Metastatic or Unresectable Clear Cell Renal Cell Carcinoma

NCT05188118 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Renal Cell Carcinoma

Interventions

DRUG: Cabozantinib
DRUG: Ipilimumab
DRUG: Nivolumab
DRUG: Lenvatinib
DRUG: Everolimus

Sponsor

Icahn School of Medicine at Mount Sinai